Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Huiying, Rao"'
Autor:
Jialin Xia, Hong Chen, Xiaoxiao Wang, Weixuan Chen, Jun Lin, Feng Xu, Qixing Nie, Chuan Ye, Bitao Zhong, Min Zhao, Chuyu Yun, Guangyi Zeng, Yuejian Mao, Yongping Wen, Xuguang Zhang, Sen Yan, Xuemei Wang, Lulu Sun, Feng Liu, Chao Zhong, Pengyan Xia, Changtao Jiang, Huiying Rao, Yanli Pang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective
Externí odkaz:
https://doaj.org/article/f8e4546b18a54e5b9dbb16a3dd39f244
Autor:
Xinxin Lu, Ren Wang, Mingjie Li, Biao Zhang, Huiying Rao, Xiaoli Huang, Xijun Chen, Yan’an Wu
Publikováno v:
BMC Medical Genomics, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Background Mutations in fibrillin-1 (FBN1) are known to be associated with Marfan syndrome (MFS), an autosomal dominant connective tissue disorder. Most FBN1 mutations are missense or nonsense mutations. Traditional molecular genetic testing
Externí odkaz:
https://doaj.org/article/17d32e9cc11943a29f881ddada315e3b
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being. Methods In this prospective multicenter obs
Externí odkaz:
https://doaj.org/article/ac6451c3d0c1414aa141f16899c06b1f
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Previous studies have indicated that HBV pregenome RNA (HBV pgRNA) could predict HBeAg seroconversion among the chronic hapatitis B (CHB) patients treated with pegylated interferon (Peg-IFN) or nucleos(t)ide analogues (NAs). Howev
Externí odkaz:
https://doaj.org/article/7b4d07e11c3b429c93721ca62ec653cc
Autor:
Rui Hua, Fei Kong, Guangming Li, Xiaofeng Wen, Yuexin Zhang, Xingxiang Yang, Chenxin Meng, Wen Xie, Yongfang Jiang, Xiaozhong Wang, Xueji Han, Yan Huang, Qing Mao, Jiefei Wang, Yujuan Guan, Jiayu Chen, Yingjie Ma, Qingfang Xiong, Hong Ma, Xuebing Yan, Huiying Rao, Yingren Zhao, Tong Sun, Liying Zhu, Xiaorong Mao, Jianqi Lian, Guojiong Deng, Yongning Xin, Yifei Wang, Yinong Ye, Bin Xu, Hainv Gao, Youwen Tan, Dongliang Li, Dongliang Yang, Minghua Su, Xiaomeng Zhang, Jie Min, Xinsheng Shi, Lai Wei, Junqi Niu
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 11, Pp 2595-2609 (2023)
Abstract Introduction A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for th
Externí odkaz:
https://doaj.org/article/4d0af3324e6e4c21a5db8711ee29c45a
Autor:
Feng Liu, Yameng Sun, Dean Tai, Yayun Ren, Elaine L. K. Chng, Aileen Wee, Pierre Bedossa, Rui Huang, Jian Wang, Lai Wei, Hong You, Huiying Rao
Publikováno v:
Diagnostics, Vol 14, Iss 16, p 1837 (2024)
This study aimed to understand the dynamic changes in fibrosis and its relationship with the evaluation of post-treatment viral hepatitis using qFibrosis. A total of 158 paired pre- and post-treatment liver samples from patients with chronic hepatiti
Externí odkaz:
https://doaj.org/article/d7c4cad561b24399ab43bd36607d3c23
Autor:
Laurent Gole, Feng Liu, Kok Haur Ong, Longjie Li, Hao Han, David Young, Gabriel Pik Liang Marini, Aileen Wee, Jingmin Zhao, Huiying Rao, Weimiao Yu, Lai Wei
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract The novel targeted therapeutics for hepatitis C virus (HCV) in last decade solved most of the clinical needs for this disease. However, despite antiviral therapies resulting in sustained virologic response (SVR), a challenge remains where th
Externí odkaz:
https://doaj.org/article/1ad235e0a7b34bf6aa2bad6e5e2b0113
Publikováno v:
Hepatology Communications, Vol 6, Iss 9, Pp 2262-2272 (2022)
Abstract Metabolic‐associated fatty liver disease (MAFLD) is a series of liver diseases based on liver steatosis and metabolic disorders. Steatosis, as the core factor in MAFLD diagnosis, and fibrosis, as the major determinant of adverse outcomes o
Externí odkaz:
https://doaj.org/article/e0f8c6844e604d4e895dbd3a05e5ce46
Publikováno v:
JGH Open, Vol 6, Iss 8, Pp 519-530 (2022)
Abstract Background and Aim Non‐alcoholic fatty liver disease (NAFLD) is common in the United States and China. We compared prevalence of metabolic syndrome (MS), hepatic steatosis and fibrosis, and quantity and quality of body fat between American
Externí odkaz:
https://doaj.org/article/4958aadf9c9d4c62b2fc4ed2f29915ea
Autor:
Bing-Yuan Wang, Lai Wei, Rui Huang, Jian-Gao Fan, Jun-Ping Shi, Yi-Min Mao, Jing-Min Zhao, Lun Gen Lu, Bi-Hui Zhong, Zheng-Sheng Zou, You-Qing Xu, Yi-Nong Ye, Longgen Liu, Lian-Jie Lin, Huiying Rao
Publikováno v:
BMJ Open, Vol 13, Iss 6 (2023)
Objectives Non-alcoholic fatty liver disease (NAFLD) is becoming the leading cause of chronic liver disease worldwide. However, treatment of NAFLD is potentially influenced by psychological conditions. Using the simplified version of the University o
Externí odkaz:
https://doaj.org/article/6dd162e1ca3e4bc38b54ef127d8b9910